-
Austria, Slovakia hit new temperature records
-
Israeli forces raid Palestinian refugee camp near Jerusalem
-
Where mountain lions roam, fewer deer in the headlights
-
Explosive drone found near Ukrainian plane at German airport
-
Alonso hails 'emotional' Mudryk return in 1-0 loss to Juventus
-
Leftist Democrat wins stunning primary victory in crucial Michigan
-
Embattled FIFA chief Infantino in emergency talks, suffers Figo blow
-
Inter Milan and AC Milan battle to 1-1 draw in Perth friendly
-
Mudryk back for Chelsea in friendly defeat to Juventus
-
Butterflies seek new habitats as climate changes: study
-
Alarm as explosive drone found near Ukrainian plane at German airport
-
'Deceitful' Infantino 'must go' says Luis Figo
-
Infantino and the failed deal affair -- What they said
-
ヌーシャ・オーベル:彼女はポツダムの抱える問題に対処できるのか?
-
누샤 오벨: 그녀가 포츠담의 문제들을 해결할 수 있을까?
-
努莎·奧貝爾:她能否應對波茨坦面臨的問題?
-
नूशा ऑबेल: क्या वह पॉट्सडैम की समस्याओं से निपटने के लिए तैयार हैं?
-
Нооша Аубель: Чи зможе вона впоратися з проблемами Потсдама?
-
Нооша Аубель: Сможет ли она справиться с проблемами Потсдама?
-
Noosha Aubel: Is she up to the task of tackling Potsdam’s problems?
-
Stocks mostly rise tracking earnings, US-Iran hopes
-
Alarm at German airport after drone found near Ukrainian plane, mid-air incident
-
Pakistan team reaches base camp with body of renowned climber killed in avalanche
-
Salah arrives in Turkey for Trabzonspor talks
-
Ceuta warns of 'unsustainable' situation for child migrants after influx
-
Embattled FIFA chief Infantino holds emergency talks with directors
-
SpaceX rocket stage believed to have slammed into Moon
-
Russian barrage on Kyiv kills 17 as Ukraine fails to down single missile
-
India monsoon floods, landslides kill more than 100 since July: officials
-
'Lost': Migrants despair after Britain expels them back to France
-
South Korea pro baseball league cancels games over heatwave
-
Cathay Pacific's profit soars 71% despite Iran war driving up fuel costs
-
Taiwan probes 17 China-funded firms over high-tech talent poaching
-
Russian barrage on Ukraine kills 15, wounds dozens more
-
Trump warns Iran to open Hormuz or get 'hit very hard'
-
South Korea police raid Starbucks HQ over 'Tank Day' fiasco
-
Factories shed workers in Bangladesh garment sector
-
Tech back in fashion as Asian markets extend rebound
-
North Korea warns of 'military options' over Japan rearmament
-
Total eclipse gives scientists chance to probe Sun's mysteries
-
Tiny light, big dream: Harvesting power from soil in Japan
-
What to know about the total solar eclipse on August 12
-
Trump admin to review 'closed' AI models before release: reports
-
'Like the end of the world': the eclipse chasers flocking to Spain
-
De Minaur fights past Duckworth in all-Aussie Montreal battle
-
Taiwan begins military drills as China pressure grows
-
High bills, cheap panels drive a Philippine solar surge
-
UK mansion where 'listeners' spied on Nazi generals becomes museum
-
Russian barrage on Ukraine kills 2, wounds dozens more
-
Sabalenka tops Uchijima in WTA Toronto opener
US authorizes fourth Covid shot for over 50s
The United States Tuesday authorized a fourth dose of either the Pfizer-BioNTech or Moderna Covid-19 vaccines for people 50 and older, as authorities warn of a possible new wave driven by the BA.2 variant.
The Food and Drug Administration (FDA) said in a statement it had based its decision on emerging evidence that an additional booster, given four months after the last, improved protection against severe Covid and wasn't associated with new safety concerns.
Additionally, people with immune compromising conditions who have already received four shots, with their latest at least four months ago, are now eligible for a fifth dose.
That includes people living with certain organ transplants.
The Pfizer vaccine will be available to immune compromised people aged 12 and over, while the Moderna vaccine will be available to those 18 and up.
"Current evidence suggests some waning of protection over time against serious outcomes from Covid-19 in older and immunocompromised individuals," senior FDA scientist Peter Marks said, explaining the decision.
The FDA said data from Israel, which had studied the effects of a fourth dose given four months after the third on 700,000 people, found the extra shot was safe.
It also cited data from a study of 154 health workers whose antibody levels, including against the Delta and Omicron variants, were restored to high levels two weeks after their fourth doses.
A study published by Israeli researchers in the New England Journal of Medicine this month indicated that three doses of current generation mRNA vaccines have hit a ceiling in terms of the immune response generated.
In other words, while three doses brings immunity levels to new heights, the fourth dose restores antibody levels to where they previously were shortly after the third.
Experts have said the benefits to younger, healthy people aren't yet clear, and say new vaccines will likely need to be developed as the virus continues to mutate.
J.Pereira--PC